Halilbasic Amira, Hotic Nrsad, Husaric Edin, Rahmanovic Emir, Halilbasic Meliha, Husaric Senada
Department of Paediatric Surgery, Children's Hospital, University Clinical Centre Tuzla, Tuzla, Bosnia and Herzegovina.
Med Arh. 2011;65(6):380-2. doi: 10.5455/medarh.2011.65.380-382.
Infantile hemangiomas (IH) are common benign tumors in infancy, affecting 5-10% of all infants and they can still cause disfigurement and serious complications depending on their location and size, which can be associated with ulcerations and haemorrhage. Since 2008, propranolol has become the first choice of therapy for complicated IH, compared to conventional approach with systemic corticosteroid therapy as first-line treatment and then interferon or vincristine as second- or third-line therapeutic agents. We report three cases of hemangioma, successfully treated with propranolol. Oral propranolol was given for a period of 6 months with monthly follow up. All cases showed dramatic response without any relapse after stopping the treatment. Propranolol is novel and safe medication for treatment of infantile hemangioma.
婴儿血管瘤（IH）是婴儿期常见的良性肿瘤，影响5%至10%的所有婴儿，并且根据其位置和大小仍可导致毁容和严重并发症，可能伴有溃疡和出血。自2008年以来，与传统方法相比，普萘洛尔已成为复杂性IH的首选治疗药物，传统方法是以全身皮质类固醇治疗作为一线治疗，然后以干扰素或长春新碱作为二线或三线治疗药物。我们报告三例血管瘤患者，用普萘洛尔成功治疗。口服普萘洛尔6个月，每月随访。所有病例均显示出显著疗效，停药后无任何复发。普萘洛尔是治疗婴儿血管瘤的新型安全药物。
